Clinical-grade ex vivo -expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

• Published in: Cytotherapy (Oxford, England) Vol. 11; no. 3; pp. 341 - 355
• Main Authors: Berg, Maria, Lundqvist, Andreas, McCoy, Philip, Samsel, Leigh, Fan, Yong, Tawab, Abdul, Childs, Richard
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.01.2009; Informa UK Ltd
• Subjects: Advanced Basic Science; Boronic Acids - pharmacology; Bortezomib; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - immunology; Carcinoma, Renal Cell - pathology; Cell Culture Techniques; Cell Proliferation; Cryopreservation; Cytokines - metabolism; Cytotoxicity, Immunologic - immunology; expansion; Fas Ligand Protein - genetics; Fas Ligand Protein - immunology; Fas Ligand Protein - metabolism; Humans; Immunophenotyping; immunotherapy; Immunotherapy - methods; K562 Cells; Killer Cells, Natural - immunology; Killer Cells, Natural - metabolism; Killer Cells, Natural - pathology; Lymphocyte Activation; natural killer cells; NK Cell Lectin-Like Receptor Subfamily K - genetics; NK Cell Lectin-Like Receptor Subfamily K - immunology; NK Cell Lectin-Like Receptor Subfamily K - metabolism; Other; Pyrazines - pharmacology; TNF-Related Apoptosis-Inducing Ligand - genetics; TNF-Related Apoptosis-Inducing Ligand - immunology; TNF-Related Apoptosis-Inducing Ligand - metabolism; Up-Regulation; natural killer cells; Bortezomib; immunotherapy; expansion

Background aims Cancer immunotherapy involving natural killer (NK) cell infusions and administration of therapeutic agents modulating the susceptibility of tumors to NK-cell lysis has been proposed recently. We provide a method for expanding highly cytotoxic clinical-grade NK cells in vitro for adop...